Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors

Area of Science:

• Immunotherapy
• Cellular Therapy
• Solid Tumor Oncology

Background:

• Chimeric antigen receptor (CAR) T cell therapy is effective for blood cancers but faces limitations in solid tumors.
• Challenges include antigen heterogeneity, immunosuppressive tumor microenvironment, and poor cell persistence.
• Diverse immune cell types are being explored as alternative CAR platforms.

Purpose of the Study:

• To review the current state of engineering various immune cells for solid tumor therapy.
• To highlight safety considerations for different CAR cell therapy approaches.
• To identify promising platforms for addressing unmet clinical needs in solid tumors.

Main Methods:

• Exploration of alternative CAR platforms including γδ T cells, NK cells, macrophages, and dendritic cells.
• Leveraging advances in pharmacological strategies, synthetic biology, and artificial intelligence for CAR design.
• Review of safety profiles for autologous, allogeneic, and in vivo CAR cell therapy.

Main Results:

• CAR NK cells offer innate cytotoxicity and safety.
• CAR macrophages demonstrate tissue infiltration and microenvironment modulation.
• CAR γδ T cells provide MHC-independent recognition.
• Advances in technology facilitate CAR design and manufacturing.

Conclusions:

• Diverse CAR immune cell platforms hold potential for overcoming solid tumor treatment barriers.
• Strategic selection of CAR cell types and integration of new technologies are crucial.
• Next-generation CAR strategies are being developed for durable immunotherapy responses in solid tumors.